Plain-English translation of NCT02638701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing , an anti-inflammatory medication, to see if it can help treat a rare and serious type of brain aneurysm called a dolichoectactic vertebrobasilar aneurysm. These aneurysms are large, oddly shaped, and located in hard-to-reach parts of the brain, making traditional surgery very risky. Researchers believe this medication may slow the aneurysm's growth or prevent it from bursting by calming down inflammation in the blood vessel walls.
These rare brain aneurysms are extremely difficult to treat with surgery or standard procedures, and without treatment they carry a significant risk of stroke or death. Lab studies have shown that reducing inflammation with this type of medication can prevent aneurysm growth, but it has never been tested in patients with this specific type of brain aneurysm before.
You likely qualify if…
You likely don't qualify if…
You would receive infusions through an IV (intravenous line) at three visits during the first two months (at weeks 0, 3, and 7), then every 8 weeks for the rest of a 12-month period. You would have MRI brain scans at the start, at 12 months, and at 24 months to see if the aneurysm is changing. The trial is small (only 8 participants total) and focuses on carefully monitoring whether this treatment is safe and whether it slows aneurysm growth.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
University of California, San Francisco
Enrollment target
~8 participants
Started
October 2024
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Daniel L Cooke, MD
University of California, San Francisco
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.